Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

B. Lowenberg; P. Muus; G.J. Ossenkoppele; P. Rousselot; J.Y. Cahn; N. Ifrah; G. Martinelli; S. Amadori; E. Berman; P. Sonneveld; M. Jongen-Lavrencic; S. Rigaudeau; P. Stockman; A. Goudie; S. Faderl; E. Jabbour; H. Kantarjian

doi:10.1182/blood-2011-07-366930

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

B. Lowenberg, P. Muus, G.J. Ossenkoppele, P. Rousselot, J.Y. Cahn, N. Ifrah, G. Martinelli, S. Amadori, E. Berman, P. Sonneveld, M. Jongen-Lavrencic, S. Rigaudeau, P. Stockman, A. Goudie, S. Faderl, E. Jabbour, H. Kantarjian

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	6030-6036
Journal	Blood
Volume	118
Issue number	23
DOIs	https://doi.org/10.1182/blood-2011-07-366930
Publication status	Published - 2011

Access to Document

10.1182/blood-2011-07-366930

Cite this

Lowenberg, B., Muus, P., Ossenkoppele, G. J., Rousselot, P., Cahn, J. Y., Ifrah, N., Martinelli, G., Amadori, S., Berman, E., Sonneveld, P., Jongen-Lavrencic, M., Rigaudeau, S., Stockman, P., Goudie, A., Faderl, S., Jabbour, E., & Kantarjian, H. (2011). Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood, 118(23), 6030-6036. https://doi.org/10.1182/blood-2011-07-366930

@article{1bd5d883d0324921b7d3d001769fb735,

title = "Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia",

author = "B. Lowenberg and P. Muus and G.J. Ossenkoppele and P. Rousselot and J.Y. Cahn and N. Ifrah and G. Martinelli and S. Amadori and E. Berman and P. Sonneveld and M. Jongen-Lavrencic and S. Rigaudeau and P. Stockman and A. Goudie and S. Faderl and E. Jabbour and H. Kantarjian",

year = "2011",

doi = "10.1182/blood-2011-07-366930",

language = "Undefined/Unknown",

volume = "118",

pages = "6030--6036",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

Lowenberg, B, Muus, P, Ossenkoppele, GJ, Rousselot, P, Cahn, JY, Ifrah, N, Martinelli, G, Amadori, S, Berman, E, Sonneveld, P, Jongen-Lavrencic, M, Rigaudeau, S, Stockman, P, Goudie, A, Faderl, S, Jabbour, E & Kantarjian, H 2011, 'Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia', Blood, vol. 118, no. 23, pp. 6030-6036. https://doi.org/10.1182/blood-2011-07-366930

TY - JOUR

T1 - Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

AU - Lowenberg, B.

AU - Muus, P.

AU - Ossenkoppele, G.J.

AU - Rousselot, P.

AU - Cahn, J.Y.

AU - Ifrah, N.

AU - Martinelli, G.

AU - Amadori, S.

AU - Berman, E.

AU - Sonneveld, P.

AU - Jongen-Lavrencic, M.

AU - Rigaudeau, S.

AU - Stockman, P.

AU - Goudie, A.

AU - Faderl, S.

AU - Jabbour, E.

AU - Kantarjian, H.

PY - 2011

Y1 - 2011

U2 - 10.1182/blood-2011-07-366930

DO - 10.1182/blood-2011-07-366930

M3 - Article

C2 - 21976672

VL - 118

SP - 6030

EP - 6036

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -